Bli medlem
Bli medlem

Du är här

2021-11-02

Amniotics AB (publ)’s Nomination Committee appointed for the Annual General Meeting (AGM) 2022

Amniotics AB (publ) hereby announces that the Nomination Committee for the AGM 2022 has been appointed.

In accordance with the instruction for the Nomination Committee, which was adopted by the AGM on April 15, 2021, the Nomination Committee shall consist of four members, one representative for each of the three largest shareholders on the last banking day in September and the Chairman of the board of directors. The “three largest shareholders” refers to the ownership grouped registered shareholders or in another way known shareholders as per the last banking day in September. Based on the above, the Nomination Committee for the AGM 2022 has been appointed and consists of:
 

  • Christer Fåhraeus, representing Theope Seed Capital AB
  • Marcus Larsson, representing Deflexum AB
  • Fredrik Tiberg, representing LSCS Invest AB
  • Peter Buhl Jensen, Chairman of the board of directors

 
Nomination Committee proposals
The Nomination Committee submits proposals to the AGM regarding inter alia the composition of the board of directors, remuneration to the board of directors, election of auditors and remuneration to the auditor.
 
Shareholders who wish to submit proposals to the Nomination Committee ahead of the AGM 2022 are welcome to contact the Nomination Committee no later than March 1, 2022.
 
by email to:
agm@amniotics.com
 
by regular mail to:
Amniotics AB (publ)
Attn: Nomination Committee
Scheelevägen 2
SE-223 63 Lund
Sweden
 
For further information, please contact:
Peter Buhl Jensen, Chairman of the board, Amniotics AB
E-mail: pbj@buhloncology.com
Phone: +45 21 60 89 22
Johny Humaloja, CFO, Amniotics AB
Phone: +46 (0) 735 06 68 56
Email: jh@amniotics.com
 

About Amniotics


Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University HospitalUniversity Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics has itsit´s headquarter in Lund, Sweden.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.
Learn more at www.amniotics.com

Attachments


Amniotics AB (publ)’s Nomination Committee appointed for the Annual General Meeting (AGM) 2022

Författare MFN